nodes	percent_of_prediction	percent_of_DWPC	metapath
Danazol—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0484	0.126	CbGbCtD
Danazol—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0455	0.118	CbGbCtD
Danazol—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0455	0.118	CbGbCtD
Danazol—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0411	0.107	CbGbCtD
Danazol—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0411	0.107	CbGbCtD
Danazol—CCL2—alveolus of lung—acquired immunodeficiency syndrome	0.0393	0.245	CbGeAlD
Danazol—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0355	0.0925	CbGbCtD
Danazol—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0345	0.0898	CbGbCtD
Danazol—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0312	0.0812	CbGbCtD
Danazol—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0312	0.0812	CbGbCtD
Danazol—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0299	0.0779	CbGbCtD
Danazol—SHBG—semen—acquired immunodeficiency syndrome	0.0105	0.0654	CbGeAlD
Danazol—CYP19A1—semen—acquired immunodeficiency syndrome	0.0085	0.0531	CbGeAlD
Danazol—AR—semen—acquired immunodeficiency syndrome	0.00752	0.047	CbGeAlD
Danazol—CCL2—endothelium—acquired immunodeficiency syndrome	0.00737	0.046	CbGeAlD
Danazol—CCL2—Chemokine receptors bind chemokines—CCL3L1—acquired immunodeficiency syndrome	0.0068	0.0515	CbGpPWpGaD
Danazol—CCL2—blood plasma—acquired immunodeficiency syndrome	0.00655	0.0409	CbGeAlD
Danazol—SHBG—blood plasma—acquired immunodeficiency syndrome	0.00382	0.0238	CbGeAlD
Danazol—CCL2—Chemokine receptors bind chemokines—CCL4—acquired immunodeficiency syndrome	0.00372	0.0282	CbGpPWpGaD
Danazol—CCL2—retina—acquired immunodeficiency syndrome	0.00358	0.0224	CbGeAlD
Danazol—CCL2—skin of body—acquired immunodeficiency syndrome	0.00315	0.0197	CbGeAlD
Danazol—GNRHR—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00301	0.0228	CbGpPWpGaD
Danazol—CCL2—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00256	0.0194	CbGpPWpGaD
Danazol—GNRHR—GPCRs, Other—ACKR1—acquired immunodeficiency syndrome	0.00255	0.0194	CbGpPWpGaD
Danazol—CCL2—lymphoid tissue—acquired immunodeficiency syndrome	0.00255	0.0159	CbGeAlD
Danazol—CCL2—Chemokine receptors bind chemokines—CCL3—acquired immunodeficiency syndrome	0.00254	0.0193	CbGpPWpGaD
Danazol—CCL2—digestive system—acquired immunodeficiency syndrome	0.00252	0.0157	CbGeAlD
Danazol—GNRHR—nervous system—acquired immunodeficiency syndrome	0.00249	0.0156	CbGeAlD
Danazol—GNRHR—central nervous system—acquired immunodeficiency syndrome	0.0024	0.015	CbGeAlD
Danazol—CCL2—blood—acquired immunodeficiency syndrome	0.0024	0.015	CbGeAlD
Danazol—CCL2—bone marrow—acquired immunodeficiency syndrome	0.00232	0.0145	CbGeAlD
Danazol—CCL2—spinal cord—acquired immunodeficiency syndrome	0.00231	0.0144	CbGeAlD
Danazol—CCL2—Chemokine receptors bind chemokines—CCR2—acquired immunodeficiency syndrome	0.0023	0.0174	CbGpPWpGaD
Danazol—CCL2—GMCSF-mediated signaling events—CSF2—acquired immunodeficiency syndrome	0.00226	0.0171	CbGpPWpGaD
Danazol—CCL2—vagina—acquired immunodeficiency syndrome	0.00222	0.0139	CbGeAlD
Danazol—CCL2—Chemokine receptors bind chemokines—CXCL12—acquired immunodeficiency syndrome	0.00216	0.0164	CbGpPWpGaD
Danazol—CCL2—Chemokine receptors bind chemokines—CXCR4—acquired immunodeficiency syndrome	0.00216	0.0164	CbGpPWpGaD
Danazol—CCL2—lung—acquired immunodeficiency syndrome	0.0021	0.0131	CbGeAlD
Danazol—CCL2—TWEAK Signaling Pathway—CCL5—acquired immunodeficiency syndrome	0.00207	0.0157	CbGpPWpGaD
Danazol—CCL2—nervous system—acquired immunodeficiency syndrome	0.00195	0.0122	CbGeAlD
Danazol—GNRHR—brain—acquired immunodeficiency syndrome	0.00191	0.0119	CbGeAlD
Danazol—CCL2—IL1 and megakaryotyces in obesity—IFNG—acquired immunodeficiency syndrome	0.0019	0.0144	CbGpPWpGaD
Danazol—CCL2—central nervous system—acquired immunodeficiency syndrome	0.00187	0.0117	CbGeAlD
Danazol—CCL2—Vitamin B12 Metabolism—CCL5—acquired immunodeficiency syndrome	0.00177	0.0134	CbGpPWpGaD
Danazol—CCL2—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00172	0.013	CbGpPWpGaD
Danazol—GNRHR—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00168	0.0128	CbGpPWpGaD
Danazol—PGR—Nuclear signaling by ERBB4—CXCL12—acquired immunodeficiency syndrome	0.00167	0.0126	CbGpPWpGaD
Danazol—CCL2—Chemokine receptors bind chemokines—CCL5—acquired immunodeficiency syndrome	0.00165	0.0125	CbGpPWpGaD
Danazol—GNRHR—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00158	0.012	CbGpPWpGaD
Danazol—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00157	0.0119	CbGpPWpGaD
Danazol—CCL2—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00155	0.0117	CbGpPWpGaD
Danazol—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.0015	0.00938	CbGeAlD
Danazol—CCL2—brain—acquired immunodeficiency syndrome	0.00149	0.00929	CbGeAlD
Danazol—CCL2—Chemokine receptors bind chemokines—CCR5—acquired immunodeficiency syndrome	0.00148	0.0112	CbGpPWpGaD
Danazol—CCL2—lymph node—acquired immunodeficiency syndrome	0.00144	0.00898	CbGeAlD
Danazol—CCL2—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.0014	0.0106	CbGpPWpGaD
Danazol—SHBG—blood—acquired immunodeficiency syndrome	0.0014	0.00874	CbGeAlD
Danazol—CCL2—Folate Metabolism—IL4—acquired immunodeficiency syndrome	0.0014	0.0106	CbGpPWpGaD
Danazol—CCL2—AP-1 transcription factor network—IL10—acquired immunodeficiency syndrome	0.00137	0.0104	CbGpPWpGaD
Danazol—CCL2—AP-1 transcription factor network—CSF2—acquired immunodeficiency syndrome	0.00136	0.0103	CbGpPWpGaD
Danazol—SHBG—bone marrow—acquired immunodeficiency syndrome	0.00135	0.00845	CbGeAlD
Danazol—CCL2—IL23-mediated signaling events—IFNG—acquired immunodeficiency syndrome	0.00134	0.0102	CbGpPWpGaD
Danazol—PGR—lymphoid tissue—acquired immunodeficiency syndrome	0.00134	0.00836	CbGeAlD
Danazol—CCL2—AP-1 transcription factor network—IL4—acquired immunodeficiency syndrome	0.00133	0.0101	CbGpPWpGaD
Danazol—AR—skin of body—acquired immunodeficiency syndrome	0.00132	0.00823	CbGeAlD
Danazol—CCL2—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00131	0.0099	CbGpPWpGaD
Danazol—CCL2—IL23-mediated signaling events—CD4—acquired immunodeficiency syndrome	0.0013	0.00983	CbGpPWpGaD
Danazol—SHBG—vagina—acquired immunodeficiency syndrome	0.0013	0.0081	CbGeAlD
Danazol—CCL2—Spinal Cord Injury—CCR2—acquired immunodeficiency syndrome	0.00127	0.00961	CbGpPWpGaD
Danazol—PGR—blood—acquired immunodeficiency syndrome	0.00126	0.00787	CbGeAlD
Danazol—CCL2—Metabolism of proteins—ENPEP—acquired immunodeficiency syndrome	0.00121	0.00919	CbGpPWpGaD
Danazol—GNRHR—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00119	0.00906	CbGpPWpGaD
Danazol—CCL2—IL23-mediated signaling events—IL2—acquired immunodeficiency syndrome	0.00119	0.00905	CbGpPWpGaD
Danazol—PGR—vagina—acquired immunodeficiency syndrome	0.00117	0.0073	CbGeAlD
Danazol—CCL2—Vitamin B12 Metabolism—ALB—acquired immunodeficiency syndrome	0.00114	0.00863	CbGpPWpGaD
Danazol—CYP19A1—blood—acquired immunodeficiency syndrome	0.00113	0.00708	CbGeAlD
Danazol—PGR—lung—acquired immunodeficiency syndrome	0.0011	0.0069	CbGeAlD
Danazol—SHBG—central nervous system—acquired immunodeficiency syndrome	0.00109	0.00683	CbGeAlD
Danazol—GNRHR—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00108	0.00822	CbGpPWpGaD
Danazol—AR—lymphoid tissue—acquired immunodeficiency syndrome	0.00107	0.00666	CbGeAlD
Danazol—AR—digestive system—acquired immunodeficiency syndrome	0.00105	0.00658	CbGeAlD
Danazol—ESR1—lymphoid tissue—acquired immunodeficiency syndrome	0.00105	0.00654	CbGeAlD
Danazol—CCL2—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00104	0.00788	CbGpPWpGaD
Danazol—CCL2—Vitamin B12 Metabolism—IFNG—acquired immunodeficiency syndrome	0.00104	0.00788	CbGpPWpGaD
Danazol—ESR1—digestive system—acquired immunodeficiency syndrome	0.00103	0.00646	CbGeAlD
Danazol—PGR—nervous system—acquired immunodeficiency syndrome	0.00102	0.00639	CbGeAlD
Danazol—AR—blood—acquired immunodeficiency syndrome	0.001	0.00627	CbGeAlD
Danazol—ESR1—blood—acquired immunodeficiency syndrome	0.000986	0.00616	CbGeAlD
Danazol—PGR—central nervous system—acquired immunodeficiency syndrome	0.000985	0.00615	CbGeAlD
Danazol—ESR1—Nuclear signaling by ERBB4—CXCL12—acquired immunodeficiency syndrome	0.000978	0.00741	CbGpPWpGaD
Danazol—AR—spinal cord—acquired immunodeficiency syndrome	0.000967	0.00604	CbGeAlD
Danazol—AR—Integrated Breast Cancer Pathway—APOBEC3G—acquired immunodeficiency syndrome	0.000962	0.0073	CbGpPWpGaD
Danazol—CCL2—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000957	0.00726	CbGpPWpGaD
Danazol—GNRHR—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000951	0.00721	CbGpPWpGaD
Danazol—CCL2—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00094	0.00713	CbGpPWpGaD
Danazol—AR—vagina—acquired immunodeficiency syndrome	0.000931	0.00581	CbGeAlD
Danazol—CCL2—Folate Metabolism—ALB—acquired immunodeficiency syndrome	0.000926	0.00702	CbGpPWpGaD
Danazol—CYP19A1—nervous system—acquired immunodeficiency syndrome	0.000921	0.00575	CbGeAlD
Danazol—GNRHR—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	0.00092	0.00697	CbGpPWpGaD
Danazol—ESR1—vagina—acquired immunodeficiency syndrome	0.000914	0.00571	CbGeAlD
Danazol—CYP19A1—central nervous system—acquired immunodeficiency syndrome	0.000886	0.00554	CbGeAlD
Danazol—AR—lung—acquired immunodeficiency syndrome	0.00088	0.0055	CbGeAlD
Danazol—CCL2—Spinal Cord Injury—IL4—acquired immunodeficiency syndrome	0.000878	0.00666	CbGpPWpGaD
Danazol—CCL2—IL23-mediated signaling events—TNF—acquired immunodeficiency syndrome	0.000869	0.00659	CbGpPWpGaD
Danazol—SHBG—brain—acquired immunodeficiency syndrome	0.000868	0.00542	CbGeAlD
Danazol—CCL2—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000866	0.00656	CbGpPWpGaD
Danazol—ESR1—lung—acquired immunodeficiency syndrome	0.000864	0.0054	CbGeAlD
Danazol—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00086	0.00652	CbGpPWpGaD
Danazol—CCL2—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	0.000845	0.00641	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—APOBEC3G—acquired immunodeficiency syndrome	0.000828	0.00628	CbGpPWpGaD
Danazol—AR—nervous system—acquired immunodeficiency syndrome	0.000815	0.00509	CbGeAlD
Danazol—CCL2—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000814	0.00617	CbGpPWpGaD
Danazol—CCL2—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000814	0.00617	CbGpPWpGaD
Danazol—CCL2—AP-1 transcription factor network—IFNG—acquired immunodeficiency syndrome	0.000806	0.00611	CbGpPWpGaD
Danazol—ESR1—nervous system—acquired immunodeficiency syndrome	0.0008	0.005	CbGeAlD
Danazol—CCL2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000792	0.006	CbGpPWpGaD
Danazol—CCL2—TWEAK Signaling Pathway—TNF—acquired immunodeficiency syndrome	0.000785	0.00595	CbGpPWpGaD
Danazol—AR—central nervous system—acquired immunodeficiency syndrome	0.000785	0.0049	CbGeAlD
Danazol—PGR—brain—acquired immunodeficiency syndrome	0.000782	0.00488	CbGeAlD
Danazol—ESR1—central nervous system—acquired immunodeficiency syndrome	0.00077	0.00481	CbGeAlD
Danazol—PGR—Cellular roles of Anthrax toxin—TNF—acquired immunodeficiency syndrome	0.00076	0.00576	CbGpPWpGaD
Danazol—PGR—lymph node—acquired immunodeficiency syndrome	0.000756	0.00472	CbGeAlD
Danazol—CCL2—Folate Metabolism—IL2—acquired immunodeficiency syndrome	0.000751	0.00569	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—APOBEC3G—acquired immunodeficiency syndrome	0.000741	0.00562	CbGpPWpGaD
Danazol—CCL2—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	0.000736	0.00558	CbGpPWpGaD
Danazol—GNRHR—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000724	0.00549	CbGpPWpGaD
Danazol—CCL2—AP-1 transcription factor network—IL2—acquired immunodeficiency syndrome	0.000717	0.00543	CbGpPWpGaD
Danazol—CCL2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000716	0.00543	CbGpPWpGaD
Danazol—CYP19A1—brain—acquired immunodeficiency syndrome	0.000704	0.00439	CbGeAlD
Danazol—CCL2—IL23-mediated signaling events—IL6—acquired immunodeficiency syndrome	0.000701	0.00532	CbGpPWpGaD
Danazol—CCL2—Validated transcriptional targets of AP1 family members Fra1 and Fra2—IL6—acquired immunodeficiency syndrome	0.000701	0.00532	CbGpPWpGaD
Danazol—CYP19A1—lymph node—acquired immunodeficiency syndrome	0.00068	0.00425	CbGeAlD
Danazol—CCL2—Vitamin B12 Metabolism—TNF—acquired immunodeficiency syndrome	0.000672	0.0051	CbGpPWpGaD
Danazol—CCL2—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	0.000671	0.00509	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00067	0.00508	CbGpPWpGaD
Danazol—GNRHR—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000655	0.00496	CbGpPWpGaD
Danazol—CCL2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000642	0.00487	CbGpPWpGaD
Danazol—CCL2—TWEAK Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.000634	0.0048	CbGpPWpGaD
Danazol—AR—brain—acquired immunodeficiency syndrome	0.000623	0.00389	CbGeAlD
Danazol—CCL2—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000619	0.00469	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000613	0.00465	CbGpPWpGaD
Danazol—ESR1—brain—acquired immunodeficiency syndrome	0.000612	0.00382	CbGeAlD
Danazol—AR—lymph node—acquired immunodeficiency syndrome	0.000602	0.00376	CbGeAlD
Danazol—ESR1—lymph node—acquired immunodeficiency syndrome	0.000591	0.00369	CbGeAlD
Danazol—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000587	0.00445	CbGpPWpGaD
Danazol—CCL2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000581	0.0044	CbGpPWpGaD
Danazol—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000577	0.00361	CbGeAlD
Danazol—PGR—Signaling by ERBB4—CXCL12—acquired immunodeficiency syndrome	0.000561	0.00425	CbGpPWpGaD
Danazol—CCL2—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000558	0.00423	CbGpPWpGaD
Danazol—CYP3A4—blood—acquired immunodeficiency syndrome	0.00055	0.00343	CbGeAlD
Danazol—CCL2—Folate Metabolism—TNF—acquired immunodeficiency syndrome	0.000547	0.00415	CbGpPWpGaD
Danazol—CCL2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000546	0.00414	CbGpPWpGaD
Danazol—CCL2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000546	0.00414	CbGpPWpGaD
Danazol—CCL2—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	0.000543	0.00411	CbGpPWpGaD
Danazol—AR—Regulation of nuclear SMAD2/3 signaling—IL10—acquired immunodeficiency syndrome	0.000536	0.00406	CbGpPWpGaD
Danazol—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000531	0.00403	CbGpPWpGaD
Danazol—CCL2—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	0.000531	0.00403	CbGpPWpGaD
Danazol—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000499	0.00379	CbGpPWpGaD
Danazol—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000499	0.00379	CbGpPWpGaD
Danazol—CCL2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000489	0.00371	CbGpPWpGaD
Danazol—Shock—Zidovudine—acquired immunodeficiency syndrome	0.000473	0.00146	CcSEcCtD
Danazol—Chills—Ritonavir—acquired immunodeficiency syndrome	0.000472	0.00146	CcSEcCtD
Danazol—CCL2—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	0.000472	0.00358	CbGpPWpGaD
Danazol—Thrombocytopenia—Zidovudine—acquired immunodeficiency syndrome	0.000471	0.00145	CcSEcCtD
Danazol—AR—Notch-mediated HES/HEY network—CD4—acquired immunodeficiency syndrome	0.000471	0.00357	CbGpPWpGaD
Danazol—Fatigue—Abacavir—acquired immunodeficiency syndrome	0.00047	0.00145	CcSEcCtD
Danazol—Vision blurred—Delavirdine—acquired immunodeficiency syndrome	0.000467	0.00144	CcSEcCtD
Danazol—Arthralgia—Indinavir—acquired immunodeficiency syndrome	0.000466	0.00144	CcSEcCtD
Danazol—Vertigo—Efavirenz—acquired immunodeficiency syndrome	0.000465	0.00144	CcSEcCtD
Danazol—Anxiety—Indinavir—acquired immunodeficiency syndrome	0.000465	0.00144	CcSEcCtD
Danazol—Hyperhidrosis—Zidovudine—acquired immunodeficiency syndrome	0.000465	0.00144	CcSEcCtD
Danazol—ESR1—AP-1 transcription factor network—IL10—acquired immunodeficiency syndrome	0.000464	0.00352	CbGpPWpGaD
Danazol—Syncope—Efavirenz—acquired immunodeficiency syndrome	0.000464	0.00143	CcSEcCtD
Danazol—Tremor—Delavirdine—acquired immunodeficiency syndrome	0.000464	0.00143	CcSEcCtD
Danazol—ESR1—AP-1 transcription factor network—CSF2—acquired immunodeficiency syndrome	0.000459	0.00348	CbGpPWpGaD
Danazol—Palpitations—Efavirenz—acquired immunodeficiency syndrome	0.000457	0.00141	CcSEcCtD
Danazol—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.000457	0.00141	CcSEcCtD
Danazol—Erythema multiforme—Lamivudine—acquired immunodeficiency syndrome	0.000457	0.00141	CcSEcCtD
Danazol—Urticaria—Nevirapine—acquired immunodeficiency syndrome	0.000455	0.00141	CcSEcCtD
Danazol—Loss of consciousness—Efavirenz—acquired immunodeficiency syndrome	0.000455	0.00141	CcSEcCtD
Danazol—Chills—Saquinavir—acquired immunodeficiency syndrome	0.000454	0.0014	CcSEcCtD
Danazol—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.000453	0.0014	CcSEcCtD
Danazol—ESR1—AP-1 transcription factor network—IL4—acquired immunodeficiency syndrome	0.000452	0.00342	CbGpPWpGaD
Danazol—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.000451	0.00139	CcSEcCtD
Danazol—Tension—Ritonavir—acquired immunodeficiency syndrome	0.000449	0.00139	CcSEcCtD
Danazol—Convulsion—Efavirenz—acquired immunodeficiency syndrome	0.000448	0.00139	CcSEcCtD
Danazol—Alopecia—Saquinavir—acquired immunodeficiency syndrome	0.000447	0.00138	CcSEcCtD
Danazol—GNRHR—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000447	0.00339	CbGpPWpGaD
Danazol—Oedema—Indinavir—acquired immunodeficiency syndrome	0.000447	0.00138	CcSEcCtD
Danazol—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.000447	0.00138	CcSEcCtD
Danazol—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000446	0.00279	CbGeAlD
Danazol—Vertigo—Delavirdine—acquired immunodeficiency syndrome	0.000445	0.00137	CcSEcCtD
Danazol—Nervousness—Ritonavir—acquired immunodeficiency syndrome	0.000445	0.00137	CcSEcCtD
Danazol—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.000444	0.00137	CcSEcCtD
Danazol—Syncope—Delavirdine—acquired immunodeficiency syndrome	0.000444	0.00137	CcSEcCtD
Danazol—Leukopenia—Delavirdine—acquired immunodeficiency syndrome	0.000443	0.00137	CcSEcCtD
Danazol—Back pain—Ritonavir—acquired immunodeficiency syndrome	0.000443	0.00137	CcSEcCtD
Danazol—CCL2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000442	0.00335	CbGpPWpGaD
Danazol—PGR—Generic Transcription Pathway—CCNT1—acquired immunodeficiency syndrome	0.000442	0.00335	CbGpPWpGaD
Danazol—CCL2—Folate Metabolism—IL6—acquired immunodeficiency syndrome	0.000441	0.00335	CbGpPWpGaD
Danazol—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.000441	0.00136	CcSEcCtD
Danazol—Arthralgia—Efavirenz—acquired immunodeficiency syndrome	0.000441	0.00136	CcSEcCtD
Danazol—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000441	0.00136	CcSEcCtD
Danazol—Muscle spasms—Ritonavir—acquired immunodeficiency syndrome	0.00044	0.00136	CcSEcCtD
Danazol—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.00044	0.00136	CcSEcCtD
Danazol—Shock—Indinavir—acquired immunodeficiency syndrome	0.00044	0.00136	CcSEcCtD
Danazol—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.000439	0.00136	CcSEcCtD
Danazol—Anxiety—Efavirenz—acquired immunodeficiency syndrome	0.000439	0.00136	CcSEcCtD
Danazol—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.000439	0.00135	CcSEcCtD
Danazol—Musculoskeletal discomfort—Zidovudine—acquired immunodeficiency syndrome	0.000438	0.00135	CcSEcCtD
Danazol—Headache—Amprenavir—acquired immunodeficiency syndrome	0.000438	0.00135	CcSEcCtD
Danazol—Thrombocytopenia—Indinavir—acquired immunodeficiency syndrome	0.000438	0.00135	CcSEcCtD
Danazol—Palpitations—Delavirdine—acquired immunodeficiency syndrome	0.000438	0.00135	CcSEcCtD
Danazol—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.000437	0.00135	CcSEcCtD
Danazol—Loss of consciousness—Delavirdine—acquired immunodeficiency syndrome	0.000435	0.00134	CcSEcCtD
Danazol—CCL2—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	0.000435	0.00329	CbGpPWpGaD
Danazol—Chills—Lamivudine—acquired immunodeficiency syndrome	0.000433	0.00134	CcSEcCtD
Danazol—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.000433	0.00134	CcSEcCtD
Danazol—Hyperhidrosis—Indinavir—acquired immunodeficiency syndrome	0.000432	0.00134	CcSEcCtD
Danazol—Paraesthesia—Zidovudine—acquired immunodeficiency syndrome	0.000432	0.00133	CcSEcCtD
Danazol—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	0.000432	0.00133	CcSEcCtD
Danazol—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000431	0.00133	CcSEcCtD
Danazol—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.00043	0.00268	CbGeAlD
Danazol—Tremor—Ritonavir—acquired immunodeficiency syndrome	0.000429	0.00133	CcSEcCtD
Danazol—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.000428	0.00132	CcSEcCtD
Danazol—Alopecia—Lamivudine—acquired immunodeficiency syndrome	0.000427	0.00132	CcSEcCtD
Danazol—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.000426	0.00132	CcSEcCtD
Danazol—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.000424	0.00131	CcSEcCtD
Danazol—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.000423	0.00131	CcSEcCtD
Danazol—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	0.000422	0.0013	CcSEcCtD
Danazol—CCL2—AP-1 transcription factor network—IL6—acquired immunodeficiency syndrome	0.000421	0.00319	CbGpPWpGaD
Danazol—Anxiety—Delavirdine—acquired immunodeficiency syndrome	0.00042	0.0013	CcSEcCtD
Danazol—CCL2—TNF alpha Signaling Pathway—TNF—acquired immunodeficiency syndrome	0.000419	0.00318	CbGpPWpGaD
Danazol—CCL2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000416	0.00315	CbGpPWpGaD
Danazol—CCL2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000416	0.00315	CbGpPWpGaD
Danazol—Shock—Efavirenz—acquired immunodeficiency syndrome	0.000416	0.00128	CcSEcCtD
Danazol—CCL2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000415	0.00315	CbGpPWpGaD
Danazol—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000415	0.00128	CcSEcCtD
Danazol—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000414	0.00128	CcSEcCtD
Danazol—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	0.000414	0.00128	CcSEcCtD
Danazol—ESR1—Regulation of nuclear SMAD2/3 signaling—IL10—acquired immunodeficiency syndrome	0.000413	0.00313	CbGpPWpGaD
Danazol—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.000413	0.00128	CcSEcCtD
Danazol—Tension—Lamivudine—acquired immunodeficiency syndrome	0.000413	0.00127	CcSEcCtD
Danazol—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000412	0.00127	CcSEcCtD
Danazol—Vertigo—Ritonavir—acquired immunodeficiency syndrome	0.000411	0.00127	CcSEcCtD
Danazol—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000411	0.00127	CcSEcCtD
Danazol—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000411	0.00127	CcSEcCtD
Danazol—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.000411	0.00127	CcSEcCtD
Danazol—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	0.00041	0.00127	CcSEcCtD
Danazol—Nervousness—Lamivudine—acquired immunodeficiency syndrome	0.000408	0.00126	CcSEcCtD
Danazol—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000408	0.00126	CcSEcCtD
Danazol—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000407	0.00126	CcSEcCtD
Danazol—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000407	0.00126	CcSEcCtD
Danazol—CCL2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000406	0.00308	CbGpPWpGaD
Danazol—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000405	0.00125	CcSEcCtD
Danazol—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000405	0.00125	CcSEcCtD
Danazol—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000405	0.00125	CcSEcCtD
Danazol—GNRHR—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000404	0.00307	CbGpPWpGaD
Danazol—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000404	0.00125	CcSEcCtD
Danazol—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000404	0.00125	CcSEcCtD
Danazol—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000402	0.00124	CcSEcCtD
Danazol—Rash—Didanosine—acquired immunodeficiency syndrome	0.000402	0.00124	CcSEcCtD
Danazol—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000401	0.00124	CcSEcCtD
Danazol—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000401	0.00124	CcSEcCtD
Danazol—Headache—Didanosine—acquired immunodeficiency syndrome	0.000399	0.00123	CcSEcCtD
Danazol—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000398	0.00123	CcSEcCtD
Danazol—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000398	0.00123	CcSEcCtD
Danazol—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000397	0.00123	CcSEcCtD
Danazol—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000397	0.00123	CcSEcCtD
Danazol—CCL2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000396	0.003	CbGpPWpGaD
Danazol—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000396	0.00122	CcSEcCtD
Danazol—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000396	0.00122	CcSEcCtD
Danazol—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000395	0.00122	CcSEcCtD
Danazol—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000395	0.00122	CcSEcCtD
Danazol—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	0.000395	0.00122	CcSEcCtD
Danazol—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000394	0.00122	CcSEcCtD
Danazol—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000394	0.00122	CcSEcCtD
Danazol—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000394	0.00122	CcSEcCtD
Danazol—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000392	0.00121	CcSEcCtD
Danazol—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000391	0.00121	CcSEcCtD
Danazol—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000391	0.00121	CcSEcCtD
Danazol—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000391	0.00121	CcSEcCtD
Danazol—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.00039	0.0012	CcSEcCtD
Danazol—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000389	0.0012	CcSEcCtD
Danazol—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000387	0.0012	CcSEcCtD
Danazol—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000385	0.00119	CcSEcCtD
Danazol—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000385	0.00119	CcSEcCtD
Danazol—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000385	0.00119	CcSEcCtD
Danazol—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000382	0.00118	CcSEcCtD
Danazol—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000382	0.00118	CcSEcCtD
Danazol—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000382	0.00118	CcSEcCtD
Danazol—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000381	0.00118	CcSEcCtD
Danazol—GNRHR—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00038	0.00288	CbGpPWpGaD
Danazol—GNRHR—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00038	0.00288	CbGpPWpGaD
Danazol—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.00038	0.00117	CcSEcCtD
Danazol—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00038	0.00288	CbGpPWpGaD
Danazol—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000379	0.00117	CcSEcCtD
Danazol—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000378	0.00117	CcSEcCtD
Danazol—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000378	0.00117	CcSEcCtD
Danazol—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000377	0.00116	CcSEcCtD
Danazol—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.000376	0.00116	CcSEcCtD
Danazol—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000375	0.00116	CcSEcCtD
Danazol—CCL2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000374	0.00284	CbGpPWpGaD
Danazol—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000374	0.00116	CcSEcCtD
Danazol—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000374	0.00115	CcSEcCtD
Danazol—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000372	0.00115	CcSEcCtD
Danazol—GNRHR—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000372	0.00282	CbGpPWpGaD
Danazol—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.00037	0.00114	CcSEcCtD
Danazol—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000368	0.00114	CcSEcCtD
Danazol—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000368	0.00114	CcSEcCtD
Danazol—CCL2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000367	0.00278	CbGpPWpGaD
Danazol—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000367	0.00113	CcSEcCtD
Danazol—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000366	0.00113	CcSEcCtD
Danazol—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000366	0.00113	CcSEcCtD
Danazol—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000365	0.00113	CcSEcCtD
Danazol—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000364	0.00113	CcSEcCtD
Danazol—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000364	0.00113	CcSEcCtD
Danazol—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000364	0.00113	CcSEcCtD
Danazol—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000363	0.00112	CcSEcCtD
Danazol—GNRHR—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000362	0.00275	CbGpPWpGaD
Danazol—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000361	0.00112	CcSEcCtD
Danazol—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000361	0.00112	CcSEcCtD
Danazol—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000361	0.00112	CcSEcCtD
Danazol—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000361	0.00111	CcSEcCtD
Danazol—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.00036	0.00111	CcSEcCtD
Danazol—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.00036	0.00111	CcSEcCtD
Danazol—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000359	0.00111	CcSEcCtD
Danazol—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000358	0.00111	CcSEcCtD
Danazol—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000357	0.0011	CcSEcCtD
Danazol—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000356	0.0011	CcSEcCtD
Danazol—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000355	0.0011	CcSEcCtD
Danazol—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000354	0.00109	CcSEcCtD
Danazol—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000353	0.00109	CcSEcCtD
Danazol—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000353	0.00109	CcSEcCtD
Danazol—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000352	0.00109	CcSEcCtD
Danazol—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000352	0.00109	CcSEcCtD
Danazol—CCL2—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	0.000351	0.00266	CbGpPWpGaD
Danazol—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.00035	0.00108	CcSEcCtD
Danazol—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000349	0.00108	CcSEcCtD
Danazol—Rash—Stavudine—acquired immunodeficiency syndrome	0.000349	0.00108	CcSEcCtD
Danazol—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000348	0.00108	CcSEcCtD
Danazol—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000348	0.00108	CcSEcCtD
Danazol—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000348	0.00107	CcSEcCtD
Danazol—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000348	0.00107	CcSEcCtD
Danazol—Headache—Stavudine—acquired immunodeficiency syndrome	0.000346	0.00107	CcSEcCtD
Danazol—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000346	0.00107	CcSEcCtD
Danazol—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000346	0.00107	CcSEcCtD
Danazol—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000345	0.00107	CcSEcCtD
Danazol—CCL2—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	0.000344	0.00261	CbGpPWpGaD
Danazol—Rash—Abacavir—acquired immunodeficiency syndrome	0.000344	0.00106	CcSEcCtD
Danazol—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000343	0.00106	CcSEcCtD
Danazol—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000343	0.00106	CcSEcCtD
Danazol—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000342	0.00259	CbGpPWpGaD
Danazol—Headache—Abacavir—acquired immunodeficiency syndrome	0.000341	0.00105	CcSEcCtD
Danazol—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.00034	0.00105	CcSEcCtD
Danazol—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.00034	0.00105	CcSEcCtD
Danazol—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.00034	0.00105	CcSEcCtD
Danazol—CCL2—TNF alpha Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.000338	0.00257	CbGpPWpGaD
Danazol—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000338	0.00104	CcSEcCtD
Danazol—AR—Generic Transcription Pathway—CCNT1—acquired immunodeficiency syndrome	0.000337	0.00255	CbGpPWpGaD
Danazol—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000336	0.00104	CcSEcCtD
Danazol—GNRHR—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000336	0.00255	CbGpPWpGaD
Danazol—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000336	0.00104	CcSEcCtD
Danazol—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000336	0.00104	CcSEcCtD
Danazol—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000334	0.00103	CcSEcCtD
Danazol—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000332	0.00102	CcSEcCtD
Danazol—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.00033	0.00102	CcSEcCtD
Danazol—ESR1—Signaling by ERBB4—CXCL12—acquired immunodeficiency syndrome	0.000329	0.0025	CbGpPWpGaD
Danazol—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000329	0.00102	CcSEcCtD
Danazol—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000329	0.00101	CcSEcCtD
Danazol—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000328	0.00101	CcSEcCtD
Danazol—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000324	0.001	CcSEcCtD
Danazol—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000323	0.000998	CcSEcCtD
Danazol—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000322	0.000995	CcSEcCtD
Danazol—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000321	0.000992	CcSEcCtD
Danazol—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000321	0.000991	CcSEcCtD
Danazol—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.00032	0.000987	CcSEcCtD
Danazol—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000319	0.000987	CcSEcCtD
Danazol—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000318	0.000982	CcSEcCtD
Danazol—AR—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000317	0.00241	CbGpPWpGaD
Danazol—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000317	0.000978	CcSEcCtD
Danazol—CCL2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000316	0.0024	CbGpPWpGaD
Danazol—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000316	0.000977	CcSEcCtD
Danazol—ESR1—ATF-2 transcription factor network—IFNG—acquired immunodeficiency syndrome	0.000313	0.00237	CbGpPWpGaD
Danazol—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000313	0.000966	CcSEcCtD
Danazol—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.00031	0.000958	CcSEcCtD
Danazol—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000308	0.000952	CcSEcCtD
Danazol—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000308	0.00095	CcSEcCtD
Danazol—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000306	0.000944	CcSEcCtD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.000305	0.00231	CbGpPWpGaD
Danazol—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000303	0.000936	CcSEcCtD
Danazol—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000303	0.000936	CcSEcCtD
Danazol—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000303	0.000936	CcSEcCtD
Danazol—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000302	0.000933	CcSEcCtD
Danazol—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000301	0.00093	CcSEcCtD
Danazol—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000299	0.000923	CcSEcCtD
Danazol—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000297	0.000917	CcSEcCtD
Danazol—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000296	0.000914	CcSEcCtD
Danazol—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000296	0.000913	CcSEcCtD
Danazol—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000295	0.000913	CcSEcCtD
Danazol—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000293	0.000907	CcSEcCtD
Danazol—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.00029	0.000896	CcSEcCtD
Danazol—GNRHR—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000289	0.00219	CbGpPWpGaD
Danazol—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000286	0.000883	CcSEcCtD
Danazol—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000286	0.000883	CcSEcCtD
Danazol—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000286	0.000882	CcSEcCtD
Danazol—CCL2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000285	0.00216	CbGpPWpGaD
Danazol—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000284	0.000879	CcSEcCtD
Danazol—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000284	0.000878	CcSEcCtD
Danazol—Rash—Indinavir—acquired immunodeficiency syndrome	0.000282	0.000871	CcSEcCtD
Danazol—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000282	0.00087	CcSEcCtD
Danazol—Headache—Indinavir—acquired immunodeficiency syndrome	0.00028	0.000865	CcSEcCtD
Danazol—ESR1—Regulation of Telomerase—IFNG—acquired immunodeficiency syndrome	0.000279	0.00212	CbGpPWpGaD
Danazol—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000279	0.000863	CcSEcCtD
Danazol—CCL2—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	0.000277	0.0021	CbGpPWpGaD
Danazol—ESR1—AP-1 transcription factor network—IFNG—acquired immunodeficiency syndrome	0.000273	0.00207	CbGpPWpGaD
Danazol—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000273	0.000842	CcSEcCtD
Danazol—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000271	0.000838	CcSEcCtD
Danazol—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000269	0.00083	CcSEcCtD
Danazol—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000268	0.000828	CcSEcCtD
Danazol—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000267	0.000826	CcSEcCtD
Danazol—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000266	0.000823	CcSEcCtD
Danazol—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000266	0.000822	CcSEcCtD
Danazol—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000266	0.00082	CcSEcCtD
Danazol—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000265	0.000818	CcSEcCtD
Danazol—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000264	0.000817	CcSEcCtD
Danazol—GNRHR—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000261	0.00198	CbGpPWpGaD
Danazol—ESR1—Generic Transcription Pathway—CCNT1—acquired immunodeficiency syndrome	0.000259	0.00197	CbGpPWpGaD
Danazol—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000258	0.000797	CcSEcCtD
Danazol—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000257	0.000794	CcSEcCtD
Danazol—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000255	0.000787	CcSEcCtD
Danazol—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000255	0.000787	CcSEcCtD
Danazol—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000254	0.000786	CcSEcCtD
Danazol—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000253	0.000782	CcSEcCtD
Danazol—CCL2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000251	0.0019	CbGpPWpGaD
Danazol—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000251	0.000775	CcSEcCtD
Danazol—ESR1—Regulation of Telomerase—IL2—acquired immunodeficiency syndrome	0.000248	0.00188	CbGpPWpGaD
Danazol—ESR1—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	0.000247	0.00187	CbGpPWpGaD
Danazol—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000247	0.000764	CcSEcCtD
Danazol—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000246	0.000761	CcSEcCtD
Danazol—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000243	0.00075	CcSEcCtD
Danazol—ESR1—AP-1 transcription factor network—IL2—acquired immunodeficiency syndrome	0.000243	0.00184	CbGpPWpGaD
Danazol—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.00024	0.000742	CcSEcCtD
Danazol—CCL2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.00024	0.00182	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.00024	0.00182	CbGpPWpGaD
Danazol—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000238	0.000735	CcSEcCtD
Danazol—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000238	0.000734	CcSEcCtD
Danazol—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000236	0.000728	CcSEcCtD
Danazol—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000235	0.000727	CcSEcCtD
Danazol—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000234	0.000723	CcSEcCtD
Danazol—GNRHR—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.00023	0.00174	CbGpPWpGaD
Danazol—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000229	0.000707	CcSEcCtD
Danazol—GNRHR—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000229	0.00173	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000228	0.00173	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000227	0.00172	CbGpPWpGaD
Danazol—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000227	0.000701	CcSEcCtD
Danazol—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000227	0.000701	CcSEcCtD
Danazol—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000227	0.0007	CcSEcCtD
Danazol—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000225	0.000696	CcSEcCtD
Danazol—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000222	0.000686	CcSEcCtD
Danazol—GNRHR—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000219	0.00166	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000219	0.00166	CbGpPWpGaD
Danazol—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000218	0.000674	CcSEcCtD
Danazol—CCL2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000217	0.00165	CbGpPWpGaD
Danazol—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000216	0.000668	CcSEcCtD
Danazol—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000216	0.000668	CcSEcCtD
Danazol—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000215	0.000664	CcSEcCtD
Danazol—GNRHR—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000215	0.00163	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000215	0.00163	CbGpPWpGaD
Danazol—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000214	0.00066	CcSEcCtD
Danazol—CCL2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000213	0.00162	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000213	0.00162	CbGpPWpGaD
Danazol—PGR—Gene Expression—CCNT1—acquired immunodeficiency syndrome	0.000213	0.00161	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000208	0.00157	CbGpPWpGaD
Danazol—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000204	0.00063	CcSEcCtD
Danazol—GNRHR—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000198	0.0015	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000195	0.00148	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000195	0.00148	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000163	0.00124	CbGpPWpGaD
Danazol—ESR1—ATF-2 transcription factor network—IL6—acquired immunodeficiency syndrome	0.000163	0.00124	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000162	0.00123	CbGpPWpGaD
Danazol—AR—Gene Expression—CCNT1—acquired immunodeficiency syndrome	0.000162	0.00123	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000161	0.00122	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.00016	0.00121	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—TAT—acquired immunodeficiency syndrome	0.00016	0.00121	CbGpPWpGaD
Danazol—Prednisone—ALB—acquired immunodeficiency syndrome	0.000157	0.289	CrCbGaD
Danazol—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	0.000157	0.00119	CbGpPWpGaD
Danazol—Norethindrone—ALB—acquired immunodeficiency syndrome	0.000155	0.284	CrCbGaD
Danazol—GNRHR—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000148	0.00113	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000148	0.00112	CbGpPWpGaD
Danazol—Methyltestosterone—ALB—acquired immunodeficiency syndrome	0.000147	0.27	CrCbGaD
Danazol—GNRHR—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000147	0.00112	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000146	0.00111	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000146	0.00111	CbGpPWpGaD
Danazol—ESR1—AP-1 transcription factor network—IL6—acquired immunodeficiency syndrome	0.000143	0.00108	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000138	0.00105	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000138	0.00105	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000136	0.00103	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000136	0.00103	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000134	0.00102	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000134	0.00102	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000134	0.00101	CbGpPWpGaD
Danazol—PGR—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	0.000131	0.00099	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000126	0.000956	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000126	0.000956	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000125	0.000949	CbGpPWpGaD
Danazol—ESR1—Gene Expression—CCNT1—acquired immunodeficiency syndrome	0.000125	0.000947	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000123	0.00093	CbGpPWpGaD
Danazol—AR—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	0.000121	0.000916	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000115	0.000874	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000115	0.000874	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	0.000103	0.000779	CbGpPWpGaD
Danazol—AR—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	9.75e-05	0.000739	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.59e-05	0.000727	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.45e-05	0.000716	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.77e-05	0.000665	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.64e-05	0.000655	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.64e-05	0.000655	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	8.55e-05	0.000648	CbGpPWpGaD
Danazol—Testosterone—ALB—acquired immunodeficiency syndrome	8.54e-05	0.157	CrCbGaD
Danazol—GNRHR—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.51e-05	0.000645	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.45e-05	0.000641	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.12e-05	0.000616	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.12e-05	0.000616	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	7.91e-05	0.0006	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.9e-05	0.000599	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.73e-05	0.000586	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.73e-05	0.000586	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	7.67e-05	0.000581	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.35e-05	0.000557	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.27e-05	0.000551	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.27e-05	0.000551	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	6.25e-05	0.000474	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.53e-05	0.000419	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.45e-05	0.000413	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.02e-05	0.00038	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.99e-05	0.000378	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.98e-05	0.000378	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.97e-05	0.000376	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	4.66e-05	0.000353	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.57e-05	0.000346	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.54e-05	0.000344	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.54e-05	0.000344	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.27e-05	0.000323	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.27e-05	0.000323	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	3.96e-05	0.0003	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.25e-05	0.000246	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.2e-05	0.000242	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.93e-05	0.000222	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.92e-05	0.000222	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.88e-05	0.000218	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—ALB—acquired immunodeficiency syndrome	2.78e-05	0.000211	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.68e-05	0.000203	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.69e-05	0.000128	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.69e-05	0.000128	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.93e-06	7.53e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	8.12e-06	6.16e-05	CbGpPWpGaD
